My investment world leads me to deal with many brokers and I am constantly amazed at the bad advice that is so prevalent in the financial industry. I think many brokerage houses remain conflicted, try as they might to be otherwise.

Here is the latest example to reach my doorstep. We have personal assets with Charles Schwab (NASDAQ: SCHW) and they publish an in-house magazine for their clients called "onInvesting". In the summer 2009 issue listed under the heading of "Expert Insight" there is an article titled "How Sector Investing Can Work for You". I could not find a link to the story online. It is written by Brad Sorenson, CFA, director, Sector Analysis, Schwab Center for Financial Research.

I know, I know. You look at the recent performace of E*Trade's (NASDAQ: ETFC) shares and you say to yourself, man, I've got to play this stock and make some return! Sure, E*Trade shares have doubled since the first of the year. But then the earnings hit the fan, my trading friends, and that double suddenly disappeared.

The brokerage reported a Q1 loss that was wider than the year-ago number. E*Trade lost 41 cents per share versus a loss of 20 cents per share in 2008. According to this source, that was a penny worse than what Wall Street was bracing itself for.

TheStreet.com's Jim Cramer is seeing signs of a coming boom, but he's still being cautious here.

If you had to define the early cycle, if you had to outline what stocks should be soaring coming out of a recession into a boom and which ones should be faltering, you would have to say the action in this market in the last month is the quintessential behavioral pattern.

What are the components of the early cycle? First, it's the homebuilders. As is typical coming out of a recession, the stocks precede the bottom of housing. That's exactly what's happening with the lowest permits and highest affordability and best mortgage rates and massive inventory. Everywhere, except on Wall Street reporting, the bottom is bursting out. When you read the lead story in the Sunday Philadelphia Inquirer, and it is all about the thousands of prospective homebuyers heading south to pick up condos and homes for half of what they were worth two years ago -- or even less -- and you know that virtually no one has broken ground in the Sunshine State in a year, you can bet that the bottom's actually behind us. This housing market has wiped out all but the most stable private builders and even the public ones are merging as we know from Pulte (NYSE: PHM) (Cramer's Take) and Centex (NYSE: CTX) (Cramer's Take). So, in the next cycle, you can see some profitability developing year over year even though the new homes don't have much margin because the foreclosed homes next door are going for a song. And don't believe this won't change the dynamic of future foreclosures. In most areas, rent is higher than the interest on mortgages, so you will find that second or third job needed to stay in your home. The incentive structure's radically different than a year ago.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Abbott Laboratories (NYSE: ABT) Q1 profit edged past expectations despite lower sales of Humira.
• AMR Corp. (NYSE: AMR) posted a smaller-than-expected Q1 loss, sending shares sharply higher.
• Baxter International Inc. (NYSE: BAX) reported better-than-expected Q1 earnings, sending share higher.
• BP (NYSE: BP) and other oil companies were downgraded due to higher environmental costs.
• Charles Schwab Corp. (NASDAQ: SCHW) Q1 earnings declined but still topped analysts' expectations.
• Chevron Corp. (NYSE: CVX) said Q1 earnings would be lower due to a weaker dollar and lower oil prices.

On Wednesday, Charles Schwab Corp. (NASDAQ: SCHW) reported that its lower first-quarter earnings easily topped analysts' estimates, and Abbott Laboratories (NYSE: ABT) said its higher first-quarter profit edged past Wall Street expectations. Shares of Schwab surged while those of Abbott Labs fell Wednesday.

San Francisco-based brokerage and investment manager Charles Schwab said it earned $218 million, or 19 cents per share, for the quarter, as compared to $305 million, or 26 cents per share, in the same period of the previous year. Total revenue fell 15% year over year to $1.11 billion.

Analyst upgrades:

• Jefferies upgraded Abiomed (NASDAQ: ABMD) to Hold from Underperform on valuation as it believes concerns over the company's Impella heart pump are priced in at current levels. The firm lowered its target price to $7 from $8.
  
• Suntrust upgraded Somanetics (NASDAQ: SMTS) to Neutral from Reduce. The firm believes most of the risk is out of Somanetics shares and that the Q1 report could be a positive catalyst.
  
• Banc of America/Merrill upgraded shares of Telecom Italia (NYSE: TI) to Buy from Neutral on valuation and believes the company's revenue trends are improving.
• China Petroleum & Chemical (NYSE: SNP) was raised to Buy from Neutral at UBS.
• Hexcel (NYSE: HXL) and Johnson Controls (NYSE: JCI) were upgraded to Buy from Neutral at Goldman.

In his Stellar Stocks Alert, newsletter advisor Richard Schmidt sees long-term opportunity in select brokerage stocks. Here, he looks at Charles Schwab (NASDAQ: SCHW) and E*Trade (NASDAQ: ETFC).

"Some of the strongest financials in the world have lost 60%, 70%, even up to 90% or more of their value in the last year. Shares of Charles Schwab have come down too. But the stock has lost less than 50%, at its worst.

"Most of that has come since October. We had hoped the stock would bottom. But the stock continued to drop through support, meaning the downtrend is still in place. We may eventually see it go down by more than 50%.

Analyst upgrades:

• Merriman upgraded shares of Akamai (NASDAQ:AKAM) to Buy from Neutral as they believe consensus expectations are now realistic and already reflect macro headwinds. Merriman also thinks the company's cost reductions could generate upside to EPS estimates.
  
• JP Morgan upgraded Novo Nordisk (NYSE:NVO) to Overweight from Neutral on expectations the company's diabetes drug will gain U.S. approval.
  
• Credit Suisse upgraded Pfizer (NYSE:PFE) to Outperform from Neutral and raised their target to $20 from $19 citing the merits of the Wyeth (WYE) deal and valuation.
• Quality Systems (NASDAQ:QSII) was upgraded to Buy from Neutral at Piper Jaffray.
  
• Parexel (NASDAQ:PRXL) was raised to Outperform from Market Perform at Wachovia.
  
• Ferro (NYSE:FOE) was upgraded at KeyBanc to Hold from Underweight.

Discount broker E*Trade (NASDAQ: ETFC) will run its famous "talking baby" TV ad during the Superbowl. It won't help the failing company. The stock is still a "sell."

E*Trade shares change hands at $1.18. That is down from a 52-week high of $5.79. For the fourth quarter of last year, the company reported a net loss of $276 million, or $0.50 per share. And, E*Trade's operating interest income, a key measurement of its health, keeps dropping. The firm said it had applied for money from the TARP but admitted there was no guarantee it would be successful in securing that funding.

E Trade Financial Corporation (NASDAQ: ETFC), which competes with TD Ameritrade Holding Corporation (NASDAQ: AMTD) and Charles Schwab (NASDAQ: SCHW), is doing splendidly today. As I write this, the stock is up well over 15%. But I would not touch this one with a ten-foot pole, as they say.

According to this article, E*Trade reported a quarterly loss on Tuesday of $0.50 per share. While that was a lot better than the $3.98 per-share loss reported in last year's Q4, it wasn't enough to beat expectations. Wall Street was hoping for a loss of $0.24 per share. E*Trade said in its press release that daily average revenue trades increased 18% and that 97,000 new accounts were captured. While both of those stats are impressive to a certain degree, an investor must keep in mind that E*Trade is a complicated story. The company really screwed itself by exposing its shareholders to so much financial risk; sure, that might be hindsight now, but it nevertheless is true. And with all the loan provisions and all the issues with the company's involvement with applying for the government's TARP initiative, etc., I can tell you that I absolutely would not want to play around with this stock.

Bank of America (NYSE: BAC) is getting $20 billion from the government to help it with its purchase of Merrill Lynch. Also, the government will protect an asset pool worth $118 billion. This morning, Bank of America also reported quarterly results, posting a net loss of $1.8 billion for the fourth quarter. For all of 2008, the bank managed to somehow post a profit of $4 billion, which is much less than its $15 billion net income from 2007. Bank of America blamed "escalating credit losses" as well as writedowns and trading losses in capital markets. The bank also reported that Merrill Lynch, which it acquired on Jan. 1 -- after the fourth quarter ended, lost more than $15 billion in the fourth quarter. BAC shares were nearly 5% higher in premarket trading after dropping over 18% Thursday.

Citigroup Inc. (NYSE: C) meanwhile will be guaranteed on $301 billion of assets. Citigroup also reported fourth-quarter results this morning, posting a net loss of about $8.3 billion, or $1.72 per share. Not surprising, it also blamed write-downs and losses in securities and banking, as well as "higher credit losses." For the full year 2008, Citigroup reported a net loss of about $18.7 billion, or $3.88 per share. Finally, Citigroup announced it was splitting into two parts: Citigroup, to handle traditional banking, and Citi Holdings, to manage the riskier assets including brokerage and retail asset management, local consumer finance and a special asset pool. Citi shares were almost 5% higher in premarket trading after dropping over 15% Thursday.

Intel Corp. (NADSAQ: INTC) reported Thursday after the close a 90% drop in fourth-quarter earnings $234 million, or 4 cents per share, compared with $2.3 billion, or 38 cents per share, in the year-ago period. Sales slumped 23%, in line with Intel's previous guidance. Still, the results were inline with Wall Street's reduced expectations. This was enough to have the stock trade 3% higher in premarket action.

After the stock market meltdown of 2008, Wall Street brokerages aren't anyone's favorites in 2009.

But some customers said they're still happy with their online broker.

A December ChangeWave survey of 3,051 consumers found that despite the extremely difficult financial market, two online brokerages still capture high customer satisfaction ratings -- Charles Schwab (NASDAQ: SCHW) and archrival, Scottrade.

Nasdaq (NASDAQ: NDAQ) closed at $23.80. Bernard Madoff of Bernard Madoff Investment Securities LLC, was arrested by Federal agents because his investment advisory business was a "giant Poinzi scheme" reports the Wall Street Journal. NDAQ January option implied volatility of 85 is above its 26-week average of 70 according to Track Data, suggesting larger price movement.

NYSE Euronext (NYSE: NYX) closed at $25.98. NYX January option implied volatility of 97 is above its 26-week average of 72 according to Track Data, suggesting larger price movement.

Charles Schwab (NASDAQ: SCHW) closed at $16.98. SCHW January option implied volatility of 99 is above its 26-week average of 61 according to Track Data, suggesting larger movement.

TD AmeriTrade (NASDAQ: AMTD) closed at $12.92. AMTD January option implied volatility of 82 is above its 26-week average of 60 according to Track Data, suggesting larger price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

I have been posting so much bad news over the last couple of years that I thought it would be interesting to try something different for a change: look for something that's truly good. If I can find it, I'll tell you what the good news is, why it's important, and what it means for the rest of the world.

Charles Schwab, Chair of Charles Schwab Corp. (NASDAQ: SCHW) sees a bright future for stocks. He pins the blame for the current mess on a 2004 SEC ruling coupled with Alan Greenspan's lax attitude towards mortgage abuses. And he has some great career advice: do what you love.

The one down note in his interview in Fortune with Geoff Colvin, author of Talent is Overrated, is that Schwab claims his firm is in "great shape." But a look at the numbers tell a different story. Its stock is down 28% this year and it burned through $1.9 billion in cash through operations and investing in the quarter ending September 2008 (although it made a $304 million profit on $1.25 billion sales). Schwab is in relatively great shape but it is not without its challenges.

On a day when the Dow Jones industrial average closed down 400 points, you may be asking yourself, 'What can I do to make myself feel better about this?'

Charles Schwab Corp. (NASDAQ: SCHW) has an idea for you: Invest more for your retirement.

Here's how the logic goes, and I agree with it (even though, of course, it is good marketing for Schwab to promulgate such ideas).

The discount broker has found in surveys that most people (63%) say they sleep better at night when they are saving for retirement, yet many people save very little for retirement each year. They also found that people save for vacation or household items before they max out their retirement plans. And most people are positively drowning in credit card debt, probably because they made those purchases and took those vacations before they'd actually saved the money (that's my sophisticated analysis there, not survey results).